The impact of the COVID-19 pandemic has raised several critical questions about the short- and medium-term implications for trial sites and sponsors.
Standard enrollment metrics won’t be enough to understand and react to this “once-in-a-generation” outbreak.
The impact of the COVID-19 pandemic is already being felt in hospital emergency rooms and ICUs around the globe. Within clinical research, uncertainties about the pharmaceutical supply chain, reallocation of medical resources, and potential restrictions on patient travel have raised critical questions about the short- and medium-term implications for trial sites and sponsors:
As we began to parse the voluminous real-time enrollment data available to us in our ContinuVue Reporting Platform, our trial recruitment tracking platform, it quickly became apparent that many of the usual enrollment metrics would not reflect the unique nature of the current outbreak. Accordingly, we set out to systematically identify and collect the relevant data points to help us understand the trajectory and model the impact of the current outbreak. Our COVID-19 dashboard synthesizes three key sources:
The results of this analysis, detailed below, indicates we have passed a probable inflection point in the outbreak that will have broad, significant impacts on clinical trial enrollment that require an immediate and fact-based response.
Patient hesitancy in the midst of the COVID-19 outbreak is most apparent when patients are provided the opportunity to connect with and visit a local research site for more information about the trial. We indexed patients’ refusal to consider a new site against pre-outbreak baseline rates for each trial, permitting us to measure changes across multiple trials (see figure 1).
Results and outlook: In the early weeks of the outbreak, patient hesitancy decreased. We believe this is potentially a result of an increase in health information-seeking behaviors as pandemic information became more prevalent. Last week, however, reversed that trend, and we noted a significant increase in patient hesitancy. We believe patient sentiment may be a significant driver of enrollment rate changes and we continue to monitor this data closely.
Continuum tracks site capacity through the velocity and volume of sites’ outreach efforts to new referrals along with their rates of scheduling screening appointments. We find their short-term response metrics to be most indicative of their focus on trial enrollment against other competing priorities (see figure 2).
Results and outlook: In the first two months of 2020, sites exhibited extremely consistent performance in reaching out to potential trial participants. However, the week of March 9 saw a major drop in responsiveness-well below levels of any time this year. While a single week cannot definitively indicate a trend, we believe site responsiveness to potentially be the single largest driver of short-term impact on enrollment performance.
To supplement the above measurements, we deployed a survey to a representative sample of 170 US sites from March 12 to 13. The key finding from this survey is that although many sites are attempting to remain on track for “business as usual”, a clear subset are already experiencing or anticipating recruitment and retention issues.
These results were consistent across site types: academic sites, medical centers, and private research sites reported equivalent levels of concern about recruitment and retention. Results did vary considerably by therapeutic area, with sites conducting trials in older or more vulnerable populations-including cardiology, rheumatology, and ophthalmology-having nearly double the number of sites that anticipate significant recruitment and retention challenges.
We believe our indices demonstrate that the week of March 9 represents a probable inflection point in patient and site behaviors in regard to clinical trials. We are currently working closely with our trial sponsors to model the impact and develop planning scenarios based on our projections of immediate impact of the pandemic. To help quantify the trajectory of patient and site change, this week we intend to:
As former FDA Secretary Scott Gottlieb noted just yesterday, the COVID-19 outbreak represents a “once in a generation” event, leaving us with few to no historical comparisons to understand its impact. We believe the most appropriate response for the clinical trial industry is to identify and track measures that are sensitive enough to reflect the rapidly-changing impact on trial recruitment and retention, and to build fact-based scenario plans to prepare sites and reassure patients that we are able and ready to support clinical research during these unpredictable months ahead.
Results of the survey, as well as real-time updates as new site responses come in, are available on the Continuum COVID-19 dashboard.
Paul Ivsin is the Vice President of Data & Analytics at Continuum Clinical